Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Efficacy and Safety of Adaptive Treatment of Acute Myeloid Leukemia (AML) Based on D14 MRD results-a Multicenter, Single-arm, Prospective Clinical Study

NCT05736978 is registered in ClinicalTrials.gov with Shanghai Tong Ren Hospital as lead sponsor.

NCT NCT05736978
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05736978 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Efficacy and Safety of Adaptive Treatment of Acute Myeloid Leukemia (AML) Based on D14 MRD results-a Multicenter, Single-arm, Prospective Clinical Study
Lead sponsor
Shanghai Tong Ren Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
March 31, 2023
Completion date
March 15, 2027
Enrollment
58 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

aml, mrd